Q-omics provides the consensus-scored GLRXP3 profile across patient tissues and cancer cell-line models. GLRXP3 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, GLRXP3 is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, GLRXP3 RNA expression shows 5,416 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, LUSC, and STAD as cancer lineages where GLRXP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLRXP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLRXP3 survival associations across molecular data types. GLRXP3 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLRXP3 RNA expression–survival associations across cancer types. High GLRXP3 expression shows unfavorable associations in PAAD and LUSC, but favorable associations in ESCA, KIRP, READ and SKCM. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify ESCA as the clearest survival context for GLRXP3 RNA expression.
This table summarizes GLRXP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for GLRXP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLRXP3 shows lower tumor expression in LUSC, PAAD and PRAD and higher tumor expression in KIRC. The LUSC box plot shows higher GLRXP3 RNA expression in normal versus tumor tissue (log2 FC = −0.254, t-test p = .002).
This table shows molecular features associated with GLRXP3 in patient tissues and cancer cell lines. In patient samples, GLRXP3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
